Pixantrone gets orphan-drug status from European regulator

12/21/2009 | Reuters

The European Medicines Agency granted orphan-drug designation to Cell Therapeutics' pixantrone as a treatment for diffuse large B-cell lymphoma. The biotech firm plans to submit the product for European approval next year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC